Nicolas Stocker
Overview
Explore the profile of Nicolas Stocker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fadel K, Siblany L, Mohty R, Stocker N, Suner L, Brissot E, et al.
Hemasphere
. 2025 Jan;
9(1):e70074.
PMID: 39872963
No abstract available.
2.
Stocker N, Alsuliman T, Corre E, Ricard L, Kaoui F, Coppo P, et al.
Clin Hematol Int
. 2025 Jan;
7(1):1-9.
PMID: 39764201
Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced...
3.
Cautela J, Croizier C, Inchiappa L, Goncalves T, Stocker N, Tchernonog E
Bull Cancer
. 2024 Nov;
111(12):1142-1153.
PMID: 39516119
The covalent Bruton tyrosine kinase inhibitors (iBTKs) have profoundly transformed the management of B-cell lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). These targeted therapies, with ibrutinib as the pioneer, have...
4.
Corbaux P, Bainaud M, Rousseau A, Try M, Saillant A, Lafargue M, et al.
Support Care Cancer
. 2024 Nov;
32(11):763.
PMID: 39482406
Purpose: Onco-nephrology is an emerging subspecialty aiming to better understand and prevent renal events in cancer patients. We assessed patients' knowledge about (1) oncological/hematological treatments induced renal toxicity and (2)...
5.
Capes A, Morin A, Banet A, Suner L, Ricard L, Corre E, et al.
Br J Haematol
. 2024 Oct;
206(1):180-185.
PMID: 39425562
Immune effector cell-associated hematotoxicity (ICAHT) is a common toxicity associated with an important morbidity after chimeric antigen receptor (CAR)-T-cell therapy. Multiple factors seem to be involved in the development of...
6.
Alsuliman T, Psimaras D, Stocker N, Sestili S, Banet A, Van de Wyngaert Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):86-88.
PMID: 39420191
No abstract available.
7.
Alsuliman T, Musiu P, Stocker N, Desnica L, El-Cheikh J, Sestili S, et al.
Lancet Haematol
. 2024 Sep;
11(10):e792-e802.
PMID: 39312925
Sexually transmitted infections (STIs) are a difficult health challenge for immunocompromised patients. Patients treated for several haematological malignancies have further compromised immune systems. Furthermore, many chemotherapies, alone or associated with...
8.
Ricard L, Cervera P, Stocker N, Corre E, Van de Wyngaert Z, Banet A, et al.
Front Immunol
. 2024 Jul;
15:1410638.
PMID: 38983865
Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by a T follicular helper cell phenotype expressing PD-1 (programmed cell death-1). AITL exhibits a poor response to conventional...
9.
Siblany L, Stocker N, Ricard L, Brissot E, Dulery R, Banet A, et al.
J Clin Immunol
. 2024 Jun;
44(6):139.
PMID: 38822857
We evaluated the impact of early recovery of mucosal-associated invariant T cells (MAIT) and gamma-delta (γδ) T cells, especially Vδ2 T cells, on the clinical outcomes of 76 patients who...
10.
Paviglianiti A, Maia T, Gozlan J, Brissot E, Malard F, Banet A, et al.
Clin Hematol Int
. 2024 May;
6(1):26-38.
PMID: 38817703
Human herpesvirus type 6 (HHV6) reactivation after haploidentical hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) has been scarcely studied, especially when antithymocyte globulin (ATG) is added to the graft-versus-host...